key: cord-0886766-a0a4ly2c authors: Hashemian, Seyed Mohammadreza; Shafigh, Navid; Afzal, Golnaz; Jamaati, Hamidreza; Mortaz, Esmaeil; Tabarsi, Payam; Marjani, Majid; Malekmohammad, Majid; Dastan, Farzaneh; Mortazavi, Seyed Mehdi; Sadr, Makan; Idani, Esmaeil; Khoundabi, Batoul; Mohamadnia, Abdolreza; Abedini, Atefeh; Kiani, Arda; Moniri, Afshin; Nadji, Seyed Alireza; Yassari, Fatemeh; Mokhber Dezfuli, Mojtaba; Pourabdollah, Mihan; Varahram, Mohammad; Eshaghi, Faezeh; Malekpour, Mahdi; Velayati, Aliakbar title: Blood Purification Techniques, Inflammatory Mediators and Mortality in COVID-19 Patients date: 2020-12-03 journal: Tanaffos DOI: nan sha: 0b857435d976739062c0a70e6db467b7c2480f73 doc_id: 886766 cord_uid: a0a4ly2c BACKGROUND: Inflammatory mediators are an important component in the pathophysiology of the coronavirus disease 2019 (COVID-19). This study aimed to assess the effects of reducing inflammatory mediators using hemoperfusion (HP) and continuous renal replacement therapy (CRRT) on the mortality of patients with COVID-19. MATERIALS AND METHODS: Twelve patients with confirmed diagnosis of COVID-19 were included. All patients had acute respiratory distress syndrome (ARDS). Patients were divided into three groups, namely, HP, CRRT and HP+CRRT. The primary outcome was mortality and the secondary outcomes were oxygenation and reduction in inflammatory mediators at the end of the study. RESULTS: Patients were not different at baseline in demographics, inflammatory cytokine levels, and the level of acute phase reactants. Half of the patients (3 out of 6) in the HP+CRRT group survived along with the survival of one patient (1 out of 2) in the HP group. All four patients in the CRRT group died. Serum creatinine (SCr), Interleukin-1 (IL1), Interleukin-6 (IL6), Interleukin-8 (IL8), partial pressure of oxygen (PaO(2)), O(2) saturation (O(2) sat), and hemodynamic parameters improved over time in HP+CRRT and CRRT groups, but no significant difference was observed in the HP group (All Ps > 0.05). CONCLUSION: Combined HP and CRRT demonstrated the best result in terms of mortality, reduction of inflammatory mediators and oxygenation. Further investigations are needed to explore the role of HP+CRRT in COVID-19 patients. In February 2020, Masih Daneshvari Hospital reported its first COVID-19 patient and became the referral center for COVID-19 cases in Iran. The pursuing high load of patients was inevitably associated with a significant mortality of patients in the intensive care unit (ICU) due to severe ARDS (4) . Data suggests that increased mortality of COVID-19 patients is associated with a profound systemic inflammatory response (5) . Various cytokines are linked to COVID-19 and associated with COVID-19 induced lung injury and ARDS. The production of a wide array of proinflammatory cytokines is significantly elevated in patients with COVID-19 compared to healthy individuals (6) . Hypercytokinemia, also known as a cytokine storm, is shown to be related to an alarming incidence of ARDS and critical illness requiring ICU admission. Plasma levels of several cytokines in COVID-19 patients could serve as potential biomarkers of disease severity in COVID-19 (7) . These findings have demonstrated the immunopathological mechanisms of COVID-19 (8) . Various therapeutic techniques should be applied to control the inflammatory storm as confounding factors exist in patients with ARDS requiring invasive mechanical ventilation (IMV). Hemoperfusion (HP) and continuous renal replacement therapy (CRRT) can increase inflammatory cytokine elimination from the bloodstream and modulate immune function and, thus, improve patient prognosis (9) . In this study, we aimed to assess the effects of CRRT, HP, and their combination on mortality in COVID-19 patients undergoing IMV admitted to Masih Daneshvari Hospital in Tehran, Iran. Various clinical indices, including the time of treatment and biochemical parameters, were analyzed to assess the effects of HP and CRRT on the patient survival and to compare the effects of these techniques to remove plasma inflammatory factors. Patients were divided into three groups (HP, CRRT, and HP+CRRT) based on their initial kidney function, glomerular filtration rate (GFR), and neutrophil gelatinaseassociated lipocalin (NGAL) as a specific biomarker of acute kidney injury (AKI), diagnosed by an increase in the serum creatinine (SCr) level of at least 0.3 mg/dL within 48 hours. Estimated GFR (eGFR) in the HP group was > 60 mL/min. In the setting of AKI, CRRT was performed. Two patients were in the HP group, four patients were in the CRRT group and six patients were in the HP+CRRT group. All clinical data were recorded and standardized in a spreadsheet by two critical care physicians who were unaware of the purpose of this study. HP and/or CRRT therapies were initiated to improve O 2 saturation and reduce proinflammatory cytokine levels (10, 11) . For every patient, sequential (sepsis-related) organ failure assessment (SOFA) score, and acute physiology and Results were presented as mean ± standard deviation. A P < 0.05 was considered statistically significant. Table 1 The overall mortality was 66.6% (8 out of 12 patients). Mortality rates were 50% in the HP group (n=2), 100% in the CRRT group (n=4), and 50% in the HP+CRRT group (n=6). The HP+CRRT group had the best overall primary and secondary outcomes. The Cox proportional hazards model for overall survival is shown in figure 2. Patients and/or next of kin provided consent for participation and publication of clinical data. All authors approved the final manuscript and consented for publication. All the data provided in the manuscript no additional supporting data. Not applicable. Not applicable. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations Reducing mortality from 2019-nCoV: host-directed therapies should be an option A Fourteen-day Experience with Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS): An Iranian Treatment Protocol Molecular pathology of emerging coronavirus infections Elevated plasma level of selective cytokines in COVID-19 patients reflect viral load and lung injury A Pathophysiologic Approach to Biomarkers in Acute Respiratory Distress Syndrome The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease Early initiation of continuous renal replacement therapy improves clinical outcomes in patients with acute respiratory distress syndrome Effect of continuous renal replacement therapy on all-cause mortality in COVID-19 patients undergoing invasive mechanical ventilation: a retrospective cohort study Coronavirus epidemic: preparing for extracorporeal organ support in intensive care Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19 pneumonia SARS and MERS: recent insights into emerging coronaviruses Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome Elevated CXCL-8 expression in bronchoalveolar lavage correlates with disease severity in patients with acute respiratory distress syndrome resulting from tuberculosis Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study We wish to thank Jafron Biomedical Co. for providing all the required equipment for HP and CRRT free of charge to COVID-19 patients.